Biovail Corporation announced that the Company will participate at the UBS Global Specialty Pharmaceuticals Conference

May 29, 2009

TORONTO--(BUSINESS WIRE)--May. 29, 2009-- Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that the Company will participate at the UBS Global Specialty Pharmaceuticals Conference in London, UK and the Goldman Sachs Annual Healthcare Conference in New York, NY.

Biovail's UBS conference presentation is scheduled for Tuesday, June 2, 2009 at 1:30 PM GMT (8:30 AM EDT). The Goldman Sachs conference presentation is scheduled for Thursday, June 11, 2009 at 11:00 AM EDT. A live and archived Webcast will be available on the Investor Relations page of Biovail's Web site at
www.biovail.com
.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company's Web site at
www.biovail.com
.

For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to
ir@biovail.com
.

Source: Biovail Corporation

Biovail Corporation
Nelson F. Isabel, (905) 286-3000
Vice President, Investor Relations & Corporate Communications

848-264-0934

©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

Powered by SITECORE